MediFind
Condition

Anaplastic Large Cell Lymphoma

Symptoms, Doctors, Treatments, Research & More

Condition 101

What is the definition of Anaplastic Large Cell Lymphoma?

Anaplastic large cell lymphoma (ALCL) is a rare type of Non-Hodgkins lymphoma. Lymphoma is a cancer of the lymph system, part of our immune system. Non-Hodgkins lymphoma involves abnormal growth of white blood cells, either T cells or B cells. Anaplastic large cell lymphoma is an aggressive cancer that usually involves the T-cells. Cancer cells in ALCL can be identified by their appearance under the microscope and by the presence of a tumor marker called CD30 or Ki-1.

There are two types of ALCL, a type that affects mainly the skin (cutaneous ALCL) and a type that affects other body organs (systmic ALCL). Systemic ALCL also has two types, ALK-positive (anaplastic lymphoma kinase) and ALK-negative. ALK-positive ALCL occurs more often in children and young adults. ALK-negative ALCL tends to occur in older adults.

The symptoms of cutaneous ALCL include red skin lesions that break open and do not heal. Sometimes cutaneous ALCL is also found in the lymph nodes. The symptoms of systemic ALCL include fever, night sweats, and weight loss (B symptoms). The cancer can be found in the bone, soft tissue, spleen, liver and skin. The cause of ALCL is unknown. One type of ALK-negative ALCL has been associated with breast implants.  ALCL is diagnosed by a biopsy of the tumor or abnormal skin and examination of the tumor cells under a microscope. Additional testing including PET scans, CT scans, MRI and a bone marrow biopsy can tell doctors if the cancer has spread to other organs.[15060 

ALCL is treated using chemotherapy, and a stem-cell transplant for people with more aggressive cancer or for ALCL that has come back. In addition, there are newer treatments that target the cancer cells directly and have been very effective. In general, ALK-positive ALCL has a better long-term outlook than ALK-negative ALCL.

What are the alternative names for Anaplastic Large Cell Lymphoma?

  • ALCL

Latest Research

Latest Advance
Study
  • Condition: Newly Diagnosed Peripheral T Cell Lymphoma
  • Journal: Genome medicine
  • Treatment Used: CEOP/IVE/GDP (CEOP, cyclophosphamide, epirubicin, vincristine and prednisone) Alternating Regimen Versus CEOP
  • Number of Patients: 106
  • Published —
The purpose of the study was to compare the effectiveness and safety of CEOP/IVE/GDP (CEOP, cyclophosphamide, epirubicin, vincristine and prednisone) Alternating Regimen Versus CEOP for the treatment of newly diagnosed peripheral T-cell lymphoma.
Latest Advance
Study
  • Condition: Primary Cutaneous Peripheral T-Cell Lymphoma Associated with Lymphomatoid Papulosis (LyP)
  • Journal: The Journal of dermatology
  • Treatment Used: Conservative Treatment
  • Number of Patients: 1
  • Published —
This case report describes a 79-year old Japanese man who developed primary cutaneous peripheral T-cell lymphoma associated with lymphomatoid papulosis (skin disease; LyP) treated with a conservative approach.

Clinical Trials

Clinical Trial
Drug
  • Status: Not yet recruiting
  • Study Type: Drug
  • Participants: 60
  • Start Date: November 14, 2020
Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen
Clinical Trial
Drug
  • Status: Not yet recruiting
  • Study Type: Drug
  • Participants: 30
  • Start Date: November 10, 2020
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies